← FDA DRUG APPROVALS

FDA ANDA · ANDA203704

CEFEPIME

Sponsor: QILU ANTIBIOTICS

APPLICATION
ANDA203704
TYPE
ANDA
ORIGINAL APPROVAL
2016-02-01
LATEST ACTION
2022-01-28
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CEFEPIME HYDROCHLORIDEPrescription
CEFEPIME HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
CEFEPIME HYDROCHLORIDEPrescription
CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFEPIME HYDROCHLORIDEPrescription
CEFEPIME HYDROCHLORIDE EQ 500MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2022-01-28Labeling · Supplement 14 · standardAP
2020-02-11Labeling · Supplement 7 · standardAP
2017-08-15Labeling · Supplement 4 · standardAP
2017-08-15Labeling · Supplement 2 · standardAP
2016-02-01UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →